Goldman Sachs Downgrades Myriad Genetics (MYGN) to Neutral Following SCOTUS Case

December 3, 2012 9:27 AM EST Send to a Friend
Get Alerts MYGN Hot Sheet
Price: $36.19 --0%

Rating Summary:
    6 Buy, 15 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade MYGN Now!
Join SI Premium – FREE
Goldman Sachs downgraded Myriad Genetics (NASDAQ: MYGN) from Buy to Neutral with a price target of $26.00 (from $34.00) after the Supreme Court of the United States (SCOTUS) agreed to hear the case against the company relating to the patentability of genes.

Given this overhang, Goldman said their buy thesis is now impaired.

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $28.72 yesterday.




You May Also Be Interested In


Related Categories

Analyst PT Change, Downgrades

Related Entities

Goldman Sachs

Add Your Comment